University at Buffalo (UB)
Stacey A. Akers M.D.
Stacey A. Akers
M.D.
Division Director Gynecologic Oncology
Department of Obstetrics and Gynecology
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Gynecologic Oncology
Education and Training:
- MBA, SUNY Buffalo (2018)
- MD, University of South Alabama College of Medicine (2003)
- BA, Spanish, Birmingham-Southern College (1999)
- BS, Biology, Birmingham-Southern College (1999)
Journal Articles:
- Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. (2021) Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. JAMA oncology (Aug), 7(1): 78-85. doi:10.1001/jamaoncol.2020.5945
- Zhang W, Klinkebiel D, Barger CJ, Pandey S, Guda C, Miller A, Akers SN, Odunsi K, Karpf AR. (2020) Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability. Cancers (Mar), 12(3). doi:10.3390/cancers12030764
- Nesline MK, DePietro P, Dy GK, Early A, Papanicolau-Sengos A, Conroy JM, Lenzo FL, Glenn ST, Chen H, Grand. (2019) Oncologist uptake of comprehensive genomic profile guided targeted therapy. Oncotarget (Jul), 10(45): 4616-4629. doi:10.18632/oncotarget.27047
- Dy GK, Nesline MK, Papanicolau-Sengos A, DePietro P, LeVea CM, Early A, Chen H, Grand. (2019) Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing. BMC medical informatics and decision making (Jan), 19(1): 14. doi:10.1186/s12911-019-0743-x
- Mark J, Argentieri DM, Gutierrez CA, Morrell K, Eng K, Hutson AD, Mayor P, Szender JB, Starbuck K, Lynam S, Blum B, Akers S, Lele S, Paragh G, Odunsi K, de Leon-Casasola O, Frederick PJ, Zsiros E. (2018) Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery. JAMA network open (Dec), 1(8): e185452. doi:10.1001/jamanetworkopen.2018.5452
- Strohl A, Mori K, Akers S, Bshara W, Buttin B, Frederick PJ, Helenowski IB, Morrison CD, Odunsi K, Schink JC, Scholtens DM, Wei JJ, Kim JJ. (2016) Synuclein-? (SNCG) expression in ovarian cancer is associated with high-risk clinicopathologic disease. Journal of ovarian research (Nov), 9(1): 75. doi:10.1186/s13048-016-0281-4
- Klinkebiel D, Zhang W, Akers SN, Odunsi K, Karpf AR. (2016) DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer. Molecular cancer research : MCR (Sep), 14(9): 787-94. doi:10.1158/1541-7786.MCR-16-0097
- Szender JB, Frederick PJ, Eng KH, Akers SN, Lele SB, Odunsi K. (2015) Evaluation of the National Surgical Quality Improvement Program Universal Surgical Risk Calculator for a gynecologic oncology service. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Mar), 25(3): 512-20. doi:10.1097/IGC.0000000000000378
- Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR. (2015) DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics (Jan), 10(8): 736-48. doi:10.1080/15592294.2015.1062206
- Akers SN, Moysich K, Zhang W, Collamat Lai G, Miller A, Lele S, Odunsi K, Karpf AR. (2014) LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecologic oncology (Feb), 132(2): 462-7. doi:10.1016/j.ygyno.2013.12.024
- Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S, Karpf AR. (2014) Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer immunology research (Jan), 2(1): 37-49. doi:10.1158/2326-6066.CIR-13-0126
- Akers SN, Groman A, Odunsi K, Lele S, Frederick PJ. (2013) Adjuvant treatment for uterine leiomyosarcoma. European journal of gynaecological oncology (Jan), 34(5): 409-14.
- Akers SN, Riebandt G, Miller A, Groman A, Odunsi K, Lele S. (2013) Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. European journal of gynaecological oncology (Jan), 34(2): 113-9.
- Mhawech-Fauceglia P, Kesterson J, Wang D, Akers S, DuPont NC, Clark K, Lele S, Liu S. (2011) Expression and clinical significance of the transforming growth factor-ß signalling pathway in endometrial cancer. Histopathology (Jul), 59(1): 63-72. doi:10.1111/j.1365-2559.2011.03892.x
- Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, Karpf AR. (2011) Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clinical cancer research : an official journal of the American Association for Cancer Research (Apr), 17(8): 2170-80. doi:10.1158/1078-0432.CCR-10-2315
- Akers SN, Odunsi K, Karpf AR. (2010) Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future oncology (London, England) (May), 6(5): 717-32. doi:10.2217/fon.10.36
Professional Memberships:
- Society of Gynecoglic Oncology (2008–present)
- American College of Obstetrics and Gynecology (2003–present)
- Buffalo Obsetrics and Gynecology Society (2003–present)